Seagen (SGEN) Stock Forecast, Price & News

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last year. There are currently 11 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGEN, but not buy additional shares or sell existing shares.
View SGEN analyst ratings or view top-rated stocks.

17 Wall Street research analysts have issued 1 year target prices for Seagen's shares. Their SGEN share price forecasts range from $129.00 to $229.00. On average, they expect the company's stock price to reach $190.47 in the next twelve months. This suggests that the stock has a possible downside of 1.6%.
View analysts price targets for SGEN or view top-rated stocks among Wall Street analysts.

Seagen's stock was trading at $128.51 at the start of the year. Since then, SGEN shares have increased by 50.6% and is now trading at $193.49.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 27th 2023.
View our SGEN earnings forecast.

Seagen Inc. (NASDAQ:SGEN) posted its earnings results on Thursday, April, 27th. The biotechnology company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.82) by $0.11. The biotechnology company earned $519.70 million during the quarter, compared to analyst estimates of $516.28 million. Seagen had a negative net margin of 31.55% and a negative trailing twelve-month return on equity of 23.00%. The firm's quarterly revenue was up 21.9% compared to the same quarter last year. During the same period last year, the company posted ($0.74) earnings per share.

ETFs with the largest weight of Seagen (NASDAQ:SGEN) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), IQ Merger Arbitrage ETF (MNA), Principal Healthcare Innovators ETF (BTEC), VanEck Biotech ETF (BBH), Vesper U.S. Large Cap Short-Term Reversal Strategy ETF (UTRN), iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ) and Goldman Sachs Future Health Care Equity ETF (GDOC).

107 employees have rated Seagen Chief Executive Officer Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among the company's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Salesforce (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA).

Seagen trades on the NASDAQ under the ticker symbol "SGEN."

Seagen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Baker BROS. Advisors LP (25.02%), BlackRock Inc. (5.97%), Wellington Management Group LLP (3.64%), State Street Corp (1.79%), Geode Capital Management LLC (1.05%) and Avoro Capital Advisors LLC (0.96%). Insiders that own company stock include Bros Advisors Lp Baker, Charles R Romp, Charles R Romp, Clay B Siegall, Clay B Siegall, Daniel G Welch, Daniel G Welch, David W Gryska, David W Gryska, Jean I Liu, Jean I Liu, Morgan E Obrien, Roger D Dansey, Roger D Dansey, Todd E Simpson, Todd E Simpson, Vaughn B Himes and Vaughn B Himes.
View institutional ownership trends.

Shares of SGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SGEN stock can currently be purchased for approximately $193.49.

Seagen (NASDAQ:SGEN) has a market capitalization of $36.28 billion and generates $2.06 billion in revenue each year. The biotechnology company earns $-610,310,000.00 in net income (profit) each year or ($3.49) on an earnings per share basis.

The company employs 3,256 workers across the globe.

Seagen's mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The official website for the company is www.seattlegenetics.com. The biotechnology company can be reached via phone at (425) 527-4000, via email at investors@seagen.com, or via fax at 425-527-4001.